Bank Of New York Mellon Corp Theseus Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$4.69 - $8.36 $203,982 - $363,601	43,493 New	43,493 $216,000
Q3 2022 Nov 14, 2022	BUY	$5.7 - $8.68 $24,698 - $37,610	4,333 Added 11.16%	43,144 $250,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $47,537 - $132,519	9,432 Added 32.1%	38,811 $214,000
Q1 2022 May 11, 2022	BUY	$8.75 - $14.51 $106,916 - $177,297	12,219 Added 71.21%	29,379 $338,000
Q4 2021 Feb 11, 2022	BUY	$8.98 - $20.09 $154,096 - $344,744	17,160 New	17,160 $217,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.